SCHEMBL17015233

SCHEMBL17015233

c1ccc(-n2ccc3c2ccc2c4ccccc4n(-c4cccc(-n5c6ccccc6c6ccccc65)c4)c23)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.47
ATM Q13315 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ALKBH5 Q6P6C2 1/20 0.34
FTO Q9C0B1 1/20 0.34
DUSP3 P51452 1/20 0.34
PLA2G4A P47712 1/20 0.32
FOLH1 Q04609 1/20 0.32
POLB P06746 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
NR4A2 P43354 1/20 0.31
KIF11 P52732 1/20 0.31
PGR P06401 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RORC P51449 1/20 0.31
GPR3 P46089 1/20 0.31
BIRC5 O15392 1/20 0.30
ALDH1A1 P00352 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15632004 0.99 KDM4E (0.44) KDM4EATML3MBTL1ALKBH5FTO
SCHEMBL17016186 0.96 L3MBTL1 (0.50) KDM4EATML3MBTL1ALKBH5FTO
SCHEMBL17015705 0.94 L3MBTL1 (0.41) KDM4EATML3MBTL1ALKBH5FTO
SCHEMBL16357559 0.92 KDM4E (0.49) KDM4EATML3MBTL1DUSP3PLA2G4A
SCHEMBL15632449 0.92 L3MBTL1 (0.41) KDM4EATML3MBTL1ALKBH5FTO
SCHEMBL15632316 0.92 KDM4E (0.49) KDM4EATML3MBTL1DUSP3PLA2G4A
SCHEMBL17015242 0.91 KDM4E (0.40) KDM4EATML3MBTL1ALDH1A1KMT2A
SCHEMBL17015238 0.91 KDM4E (0.40) KDM4EATML3MBTL1KMT2A
SCHEMBL17015237 0.91 KDM4E (0.40) KDM4EATML3MBTL1KMT2A
SCHEMBL16357549 0.91 KDM4E (0.55) KDM4EATML3MBTL1ALKBH5FTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-9837618-B2 Compound and organic electroluminescence device including thesame DOOSAN CORPORATION (KR) 2017-12-05 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME DOOSAN CORPORATION (KR) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150236272-A1 NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE INCLUDING THESAME INMT, IDO1, IDO2 KDM4E 1286/4885ATM 3623/4885L3MBTL1 533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.